3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
15
Withdrawn
3
Unknown
3
Available
3
No longer available
2
Active not recruiting
2
Terminated
1
Recruiting
1
Not yet recruiting
1
Approved for marketing
1
Sponsor Class
OTHER
3
NIH
1
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Pheochromocytoma
1
Paraganglioma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Radiotherapy
91
pembrolizumab
88
Cyclophosphamide
84
Gemcitabine
70
Cisplatin
70
Magnetic Resonance Spectroscopy
65
Carboplatin
60
Radiosurgery
55
Paclitaxel
55
Nivolumab
48
Dexamethasone
45
Bevacizumab
42
Biopsy
41
Fluorouracil
39
durvalumab
37
Surveys and Questionnaires
36
Docetaxel
36
fludarabine
35
Doxorubicin
35
Radiation
33
Oxaliplatin
33
Capecitabine
33
Rituximab
32
fludarabine phosphate
31
Leucovorin
31
Cytarabine
30
Melphalan
29
Etoposide
28
Pemetrexed
27
Irinotecan
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Withdrawn
×
OTHER
×
3-Iodobenzylguanidine
×
Clear all
NCT04614766
2024-04-29
SPORE-3
University of Iowa
Phase 1/2
Withdrawn
NCT04831567
2022-05-19
MIBNET
AC Camargo Cancer Center
Phase 2
Withdrawn
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn